title: Morbidity and mortality in rheumatoid patients during treatment with adalimumab and infliximab.
authors.forename: E
authors.initials: E
authors.lastname: Molloy
authors.forename: S
authors.initials: S
authors.lastname: Ramakrishnan
authors.forename: E
authors.initials: E
authors.lastname: Murphy
authors.forename: M
authors.initials: M
authors.lastname: Barry
mesh_terms: D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000069285:Infliximab; D000068879:Adalimumab